CN Patent

CN109152780B — 用于治疗结晶性关节病症的cxcr-2抑制剂

Assigned to Ardea Biociences Inc · Expires 2021-10-01 · 5y expired

What this patent protects

N‑(2‑((2,3‑二氟苄基)硫基)‑6‑(((2R,3S)‑3,4‑二羟基丁‑2‑基)氧基)嘧啶‑4‑基)氮杂环丁烷‑1‑磺酰胺(化合物3)和N‑(6‑(((2R,3S)‑3,4‑二羟基丁‑2‑基)氧基)‑2‑((4‑氟苄基)硫基)嘧啶‑4‑基)‑3‑甲基氮杂环丁烷‑1‑磺酰胺(化合物4)是已知的趋化因子调节剂，因此可用于治疗其中趋化因子受体活性的调节对其有益的疾病/病况。具体而言，本文提供了用于治疗和预防痛风的组合物和方法。

USPTO Abstract

N‑(2‑((2,3‑二氟苄基)硫基)‑6‑(((2R,3S)‑3,4‑二羟基丁‑2‑基)氧基)嘧啶‑4‑基)氮杂环丁烷‑1‑磺酰胺(化合物3)和N‑(6‑(((2R,3S)‑3,4‑二羟基丁‑2‑基)氧基)‑2‑((4‑氟苄基)硫基)嘧啶‑4‑基)‑3‑甲基氮杂环丁烷‑1‑磺酰胺(化合物4)是已知的趋化因子调节剂，因此可用于治疗其中趋化因子受体活性的调节对其有益的疾病/病况。具体而言，本文提供了用于治疗和预防痛风的组合物和方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN109152780B
Jurisdiction
CN
Classification
—
Expires
2021-10-01
Drug substance claim
No
Drug product claim
No
Assignee
Ardea Biociences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.